KJ-C2114

KJ-C2114 is an allogeneic (universal) CAR T-cell therapy product candidate developed by CARsgen Therapeutics for the treatment of solid tumors. It utilizes the THANK-u Plus technology platform, which enables the production of off-the-shelf CAR T cells from healthy donors, rather than requiring autologous (patient-derived) cells. The specific target antigen for KJ-C2114 has not been publicly disclosed as of June 2025. The therapy is designed to address challenges in treating solid tumors with cell therapies and aims to improve accessibility and efficacy compared to traditional autologous CAR-T approaches. Preclinical studies are ongoing, with plans for clinical proof-of-concept data disclosure in late 2024[1][7][9][10].